Adam Gehring

Chairs: Robert Gish and Marc Ghany

• 08:40 a.m. - 09:00 a.m. New guidelines and re-thinking HBV nomenclature for therapeutic endpoints - Carla Coffin
• 09:00 a.m. - 09:20 a.m. Will long acting NA's help our goals to achieve HBV cure or not? - Mark Sulkowski
• 09:20 a.m. - 09:40 a.m. Real-world HBsAg levels and the impact HBsAg cut-offs for clinical trial enrollment - Man-Fung Yuen
• 09:40 a.m. - 10:10 a.m. Discussion

Chairs: Ira Jacobson and Maura Dandri

• 10:30 a.m. - 10:50 a.m. Gene and Epigenome editing: what is the current knowledge on efficacy and risks? - Fabien Zoulim
• 10:50 a.m. - 11:10 a.m. Advances in HDV treatment: Bulevirtide vs. mAb vs. small molecule, is there a front runner? - Pietro Lampertico
• 11:10 a.m. - 11:30 a.m. Immune dysfunction vs. exhaustion - splitting hairs or real impact on immunotherapy - Georg Lauer
• 11:30 a.m. - 12:00 p.m. Discussion

Chairs: Raymond Chung and Barbara Rehermann

• 1:00 p.m. - 1:20 p.m. Translational immunology in oncology: a successful paradigm for cure studies? - David Brooks
• 1:20 p.m. - 1:30 p.m. Efficacy of therapeutic vaccination with a novel checkpoint modifier - Sue Currie
• 1:30 p.m. - 1:40 p.m. Leveraging prior vaccination to enhance functional cure rates in siRNA/IFN-α combination studies - David Margolis
• 1:40 p.m. - 1:50 p.m. ImmTAV®: Soluble, bi-specific T cell receptors to target HBsAg-positive hepatocytes - Lucy Dorrell
• 1:50 p.m. - 2:00 p.m. Anti-HBs combination therapies for treatment in HBV/HDV patients - Michael Chattergoon
• 2:00 p.m. - 2:40 p.m. Discussion

Chairs: Harry Janssen and Raymond Schinazi

• 3:10 p.m. - 3:30 p.m. Universal Standards for new HBV biomarkers to improve their utility - Jordan Feld
• 3:30 p.m. - 3:40 p.m. Evidence for durable HBsAg declines after long-term CAM therapies - Tse-I Lin
• 3:40 p.m. - 3:50 p.m. RNA interference with ASO: Is functional cure sustained long-term?
• 3:50 p.m. - 4:00 p.m. RNA interference with ASO: Latest results from new kid on the block
• 4:00 p.m. - 4:10 p.m. Bulevirtide + IFN-α in long-term treated HDV patients: optimal duration for sustained responses - Amos Lichtman
• 4:10 p.m. - 4:25 p.m. Gene and epigenomic editing: early results in 3 elevator pitches
• 4:25 p.m. - 4:55 p.m. Discussion

Harry Janssen